Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
46 NC counties are under alert, including Johnston County.
Program
On WRAL at 7:30: Alarming rise of teen vaping in NC, A WRAL Documentary on how harmful products are marketed to children.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
161.15
+0.55 (+0.34%)
Streaming Delayed Price
Updated: 3:09 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
Today 11:00 EDT
Via
Benzinga
Why Masimo Stock Crushed the Market Today
September 25, 2024
The company seems to be effecting a smooth transition in its leadership.
Via
The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
These dividend players could lift your portfolio no matter what the market is doing.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
September 23, 2024
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics.
Via
Chartmill
The Latest Analyst Ratings For Johnson & Johnson
September 19, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Johnson & Johnson
September 12, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
September 21, 2024
This healthcare blue chip is making all the right moves to reward shareholders.
Via
The Motley Fool
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations.
Via
Benzinga
Exposures
Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic...
Via
Benzinga
Exposures
Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
September 19, 2024
This two-step strategy could set investors up with a large sum of passive income in retirement.
Via
The Motley Fool
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
September 12, 2024
Via
Benzinga
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
September 12, 2024
Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regular $500 monthly?
Via
Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
September 11, 2024
The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and reviewing existing literature to assess potential risks of metal exposure.
Via
Benzinga
Exposures
Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
September 11, 2024
Johnson & Johnson is facing a lawsuit from Associated Production Music for allegedly using unlicensed music in nearly 80 videos, potentially resulting in $12 million in damages under copyright law.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
September 11, 2024
Johnson & Johnson announced promising Phase 2 SKIPPirr study results for Rybrevant in reducing infusion-related reactions in NSCLC patients.
Via
Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
September 11, 2024
You can take these dividends straight to the bank.
Via
The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.
Via
Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
September 10, 2024
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.
Via
Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
September 06, 2024
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report."
Via
Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 06, 2024
Via
Benzinga
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
September 05, 2024
Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claimant payouts.
Via
Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
September 05, 2024
Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.